BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Chinese Patent Office
Daiichi Sankyo
US Department of Justice
UBS
Fuji
Accenture
Federal Trade Commission
Healthtrust

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 091163

« Back to Dashboard

NDA 091163 describes FOSINOPRIL SODIUM, which is a drug marketed by Actavis Labs Fl Inc, Apotex Inc, Aurobindo Pharma Ltd, Invagen Pharms, Prinston Inc, Ranbaxy Labs Ltd, Teva, Upsher-smith Labs, Watson Labs, Aurobindo Pharma, Emcure Pharms India, Mylan, Sandoz, and Sun Pharm Inds Ltd, and is included in twenty NDAs. It is available from sixteen suppliers. Additional details are available on the FOSINOPRIL SODIUM profile page.

The generic ingredient in FOSINOPRIL SODIUM is fosinopril sodium; hydrochlorothiazide. There are six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the fosinopril sodium; hydrochlorothiazide profile page.
Summary for 091163
Tradename:FOSINOPRIL SODIUM
Applicant:Aurobindo Pharma Ltd
Ingredient:fosinopril sodium
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 091163
Medical Subject Heading (MeSH) Categories for 091163
Suppliers and Packaging for NDA: 091163
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FOSINOPRIL SODIUM fosinopril sodium TABLET;ORAL 091163 ANDA Aurobindo Pharma Limited 65862-471 65862-471-30 30 TABLET in 1 BOTTLE (65862-471-30)
FOSINOPRIL SODIUM fosinopril sodium TABLET;ORAL 091163 ANDA Aurobindo Pharma Limited 65862-471 65862-471-90 90 TABLET in 1 BOTTLE (65862-471-90)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength10MG
Approval Date:Mar 30, 2011TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength20MG
Approval Date:Mar 30, 2011TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength40MG
Approval Date:Mar 30, 2011TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
US Department of Justice
AstraZeneca
Moodys
Merck
Farmers Insurance
McKinsey
Teva
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot